|
|
Article: Research by G. Okugawa and colleagues in schizophrenia provides new insights.
- Article from:
- Biotech Week
- Article date:
- July 1, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
"Perospirone is classified as a second-generation antipsychotic agent for the treatment of schizophrenia. Perospirone binds with high affinity to serotonin 5-HT2A receptors and dopamine D2 receptors," investigators in Osaka, Japan report (see also Schizophrenia).
"There are no reports of clinical comparisons of perospirone and risperidone in multicenter studies. To clarify the clinical traits of perospirone in the treatment of schizophrenia, the clinical efficacies and side-effects of perospirone and risperidone were compared in a randomized clinical multicenter trial. Sixty-six schizophrenia patients were enrolled in the trial. The Positive and Negative Syndrome ...
Related newspaper, magazine, and journal articles:
|
|
Article: Study findings from Geneva University, Department of ...
Biotech Week;
September 10, 2008 ;
700+ words
... ... Perez and colleagues, Geneva University, Department of Clinical Neurosciences. The researchers concluded: "Considering that present ... Hospitals, Geneva University Hospitals, Dept. of Clinical Neurosciences, Rue Micheli-du-Crest 24, Geneva, Switzerland ...
|
|